Antibody for Symptomatic COVID-19 Prophylaxis Submitted for Emergency Use Authorization


AZD7442 (AstraZeneca), a long-acting antibody combination, reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo.

AstraZeneca is seeking an Emergency Use Authorization (EUA) from the FDA for AZD7442, a long-acting antibody combination (LAAB) for prophylaxis of symptomatic COVID-19, according to a statement from the company.

“Vulnerable populations such as the immunocompromised often aren’t able to mount a protective response following vaccination and continue to be at risk of developing COVID-19,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a press release. “With this first global regulatory filing, we are one step closer to providing an additional option to help protect against COVID-19 alongside vaccines. We look forward to sharing AZD7442 data for the treatment of COVID-19 later this year.”

The EUA request includes safety and efficacy data from the PROVENT trial, which showed that AZD7442 reduced the risk of developing symptomatic COVID-19 by 77% compared to a placebo.

More than 75% of individuals with comorbidities had an increased risk of severe disease or a reduced immune response to vaccination, so they had a greater need for additional protection from COVID-19 infection.

The drug was well-tolerated in the study. Prior results from the PROVENT trial showed AZD7442 reduced the risk of developing symptomatic COVID-19 by 77% (95% CI 46, 90), compared to placebo.

If granted by the FDA, the drug would be the first LAAB to receive an EUA for COVID-19 prevention.


AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US. AstraZeneca. News release. October 5, 2021. Accessed October 5, 2021.

Related Videos
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS |
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz -
Image credit: New Africa |
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages -
Image credit: alicja neumiler |
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image Credit: Pixel-Shot |
Pharmacist holding medicine box and capsule pack in pharmacy drugstore. -- Image credit: I Viewfinder |
© 2024 MJH Life Sciences

All rights reserved.